By comparison, prostate cancer figures are somewhat better, with about one-third of patients surviving beyond two years. Elsewhere in the world, these figures are nearly 100 per cent for prostate ...

Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation ...

Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen receptor inhibitors in prostate cancer.

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Captain Wild Bill Wichrowski has been open with Deadliest Catch fans about his cancer battle. Here's the latest update.

Patients with mHSPC benefited from darolutamide + ADT + docetaxel irrespective of age (<75 years and ≥75 years), with consistent improvements in overall survival, time to mCRPC, and time to initiation ...

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.